External
2025.09.23
“K-Bio” Sets Its Sights on the Latin American Market
Dong-A ST is pursuing a multifaceted strategy in the Latin American market.
Last June, at the SOCESP 2025 held in São Paulo, Brazil, the company showcased its remote patient monitoring platform “HiCardi Plus” together with its local partner CARDIO WEB, marking a full-scale entry into the Brazilian market.
In particular, its flagship growth hormone product “Grottropin” recorded overseas sales of KRW 5.8 billion in 2024, a 30.4 percent increase year on year, maintaining strong growth momentum in the global market. The overseas business division is focusing on securing markets worldwide, including Latin America, through an R&D-driven approach based on its proprietary pipeline of products such as growth hormones and anti-diabetic drugs.
